Novel High Efficient Coatings for Anti-Microbial Surgical Sutures Using Chlorhexidine in Fatty Acid Slow-Release Carrier Systems

Andreas Obermeier1*, Jochen Schneider2, Steffen Wehner1, Florian Dominik Matl1, Matthias Schieker3, Rüdiger von Eisenhart-Rothe1, Axel Stemberger1, Rainer Burgkart1

1 Klinik für Orthopädie und Sportorthopädie, Klinikum rechts der Isar, Technische Universität München, München, Bayern, Germany, 2 Institut für Mikrobiologie, Immunologie und Hygiene, Klinikum rechts der Isar, Technische Universität München, München, Bayern, Germany, 3 Experimentelle Chirurgie und Regenerative Medizin, Klinik für Chirurgie, Klinikum der Universität München, München, Bayern, Germany

Abstract

Sutures can cause challenging surgical site infections, due to capillary effects resulting in bacteria permeating wounds. Anti-microbial sutures may avoid these complications by inhibiting bacterial pathogens. Recently, first triclosan-resistances were reported and therefore alternative substances are becoming clinically relevant. As triclosan alternative chlorhexidine, the “gold standard” in oral antiseptics was used. The aim of the study was to optimize novel slow release chlorhexidine coatings based on fatty acids in surgical sutures, to reach a high anti-microbial efficacy and simultaneously high biocompatibility. Sutures were coated with chlorhexidine laurate and chlorhexidine palmitate solutions leading to 11, 22 or 33 µg/cm drug concentration per length. Drug release profiles were determined in aqueous elutions. Antibacterial efficacy against Staphylococcus aureus was assessed in agar diffusion tests. Biocompatibility was evaluated via established cytotoxicity assay (WST-1). A commercially triclosan-containing suture (Vicryl Plus), was used as anti-microbial reference. All coated sutures fulfilled European Pharmacopoeia required tensile strength and proved continuous slow drug release over 96 hours without complete wash out of the coated drug. High anti-microbial efficacy for up to 5 days was observed. Regarding biocompatibility, sutures using 11 µg/cm drug content displayed acceptable cytotoxic levels according to ISO 10993-5. The highest potential for human application were shown by the 11 µg/cm chlorhexidine coated sutures with palmitic acid. These novel coated sutures might be alternatives to already established anti-microbial sutures such as Vicryl Plus in case of triclosan-resistance. Chlorhexidine is already an established oral antiseptic, safety and efficacy should be proven for clinical applications in anti-microbial sutures.

Citation: Obermeier A, Schneider J, Wehner S, Matl FD, Schieker M, et al. (2014) Novel High Efficient Coatings for Anti-Microbial Surgical Sutures Using Chlorhexidine in Fatty Acid Slow-Release Carrier Systems. PLoS ONE 9(7): e101426. doi:10.1371/journal.pone.0101426

Editor: Ali Al-Ahmad, University Hospital of the Albert-Ludwigs-University Freiburg, Germany

Received February 27, 2014; Accepted June 5, 2014; Published July 1, 2014

Copyright: © 2014 Obermeier et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was financially supported by the Heraeus Medical GmbH, Wehrheim, Germany [http://www.heraeus-medical.com/de/home_15.html]. Within the Klinikum rechts der Isar, Technische Universität München the external funding number was 8895117_HeraeusCoating. This work was supported by the German Research Foundation (DFG) and the Technische Universität München within the funding programme Open Access Publishing. The funder’s financial support does not alter the authors’ adherence to PLOS ONE policies on sharing data and materials. The funding organization didn’t play any role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript and only provided financial support and research materials.

Competing Interests: The authors have declared that no competing interests exist.

* Email: aobermeier@tum.de

Introduction

Surgical site infections (SSI) are still challenging complications after operations despite of established systemic antibiotic prophylaxis today [1]. Reported rates for SSI are usually in the range of 2.5–25% e.g. for colorectal surgery [4]. In case of infection, further surgical interventions become necessary followed by a prolongation of hospitalization up to 10 days [2]. In conclusion, this means higher treatment costs of about 50,000 US$ per case on average [5] for the healthcare system as well as an elevated risk profile for the individual patient.

The presence of foreign material increases the risk of infections [6], especially surgical sutures can act as a wick for SSI [7]. So pathogens from the natural skin flora can easily enter wounds via capillary action. After having attached to suture surfaces the pathogens proliferate and are then able to form biofilms difficult to treat [8,9]. One potential solution approach to prevent this process is the use of anti-microbial coated sutures. At present, all commercially available anti-microbial sutures are exclusively coated with triclosan such as Vicryl Plus, Monocryl Plus, and PDS Plus [10].

In vitro studies using triclosan for anti-microbial sutures, e.g. Vicryl Plus, have resulted in a highly efficient defense against various bacterial pathogens [11,12]. In vivo studies for sternum surgery [13], abdominal wall closure [14], and cerebrospinal fluid shunting procedures [15] indicate significantly lower infection rates for surgical interventions using triclosan coated anti-microbial sutures [16]. In contrast, for some indications there is an ongoing controversial discussion [10,17], such as appendicitis, breast cancer and colorectal surgery [4,18–20].

The main disadvantage of the so far predominantly used antimicrobial triclosan is its wide non-medical use in cosmetics, hygiene- and household products [21]. First research groups reported resistances of bacteria against triclosan and warnings of
Table 1. Prepared anti-microbial sutures and normalized weights of chlorhexidine.

| ratio of chlorhexidine in fatty acid (%) | weight of chlorhexidine (mg) | weight of lauric-/palmitic acid (mg) | normalized drug weight (µg/cm) | coating type and abbreviation for coated sutures |
|----------------------------------------|-----------------------------|------------------------------------|-------------------------------|-----------------------------------------------|
| 20                                     | 0.44                        | 1.76                               | 11                            | chlorhexidine-lauric acid CL11                  |
|                                        |                             |                                    |                               | chlorhexidine-palmitic acid CP11               |
| 40                                     | 0.88                        | 1.32                               | 22                            | chlorhexidine-lauric acid CL22                  |
|                                        |                             |                                    |                               | chlorhexidine-palmitic acid CP22               |
| 60                                     | 1.32                        | 0.88                               | 33                            | chlorhexidine-lauric acid CL33                  |
|                                        |                             |                                    |                               | chlorhexidine-palmitic acid CP33               |

Amount of chlorhexidine on anti-microbially coated sutures after preparation. The mean coating weight of 40 cm suture samples were determined at 2.2 ± 0.2 mg. The same amounts of chlorhexidine were calculated for the coating types (CL, CP) inside coating solutions (n = 10). The weights on coated sutures for drug contents, fatty acid carriers and normalized mean drug weight per cm suture are given above.

doi:10.1371/journal.pone.0101426.t001

potential pathogen selections [22,23]. Therefore, we were looking for new alternative substances and chose chlorhexidine to equip surgical sutures anti-microbially. This antiseptic is effective against a broad spectrum of relevant pathogens including clinically problematic bacteria like *Staphylococcus aureus* [24]. Besides the known spectrum chlorhexidine is already approved in a variety of medical applications as coating for medical devices [25–27], skin antiseptic [28,29] or as well as oral antiseptic [30].

In a first feasibility study we could show that chlorhexidine coated sutures demonstrated high efficacy against *S. aureus* with the disadvantage of drug concentration related cytotoxicity [31]. Anti-microbial sutures must fulfill a balancing act between inhibiting bacteria and sustaining biocompatibility to the surrounding eukaryotic tissue cells.

The aim of this study was therefore the optimization of new chlorhexidine fatty acid coating formulations for anti-microbial sutures in regard to their drug concentration. We achieved high anti-microbial efficacy over several days combined with ISO 10993-5 required biocompatibility by variation of drug concentrations at 11, 22 or 33 µg per cm suture. Anti-microbiologically coated sutures were evaluated by measuring tensile strength, inhibition zones, and drug release profiles. These investigations were compared to commercially available plain sutures and triclosan containing Vicryl Plus, as anti-microbial reference.

**Materials and Methods**

**Surgical sutures**

Plain braided sutures (Gunze Ltd., Japan) made of polyglycolic acid (PGA) without the usual fatty acid coating to avoid sewing effects were used for the preparation of the anti-microbial sutures. As reference one triclosan-containing absorbable suture Vicryl Plus (Ethicon GmbH, Germany) and two standard absorbable sutures PGA Resorba (Resorba GmbH, Germany) and Vicryl (Ethicon GmbH, Germany) were used. All sutures used in experiments corresponded to United States Pharmacopeia standard 1 (USP 1).

**Anti-microbial coating solutions**

Anti-microbial coating solutions were prepared by dissolving a fatty acid (palmitic or lauric acid) and chlorhexidine in 99.8% ethanol (C. Roth GmbH, Germany (CR)). In order to prepare the solutions for suture coatings having a mass content of 5% (w/w), 395.0 mg of the corresponding fatty acid and the antiseptic drug were dissolved in 10.0 ml (7.9 g) ethanol. In particular, two groups of coating types were produced. Group I (CL): Chlorhexidine diacetate (Sigma-Aldrich GmbH, Germany) in lauric acid as drug carrier (CR), Group II (CP): Chlorhexidine diacetate in the drug carrier palmitic acid (CR). For each type of coating three solutions with 20%, 40% or 60% (w/w) drug concentration were formulated. The percentage of drug was related to the 5% total mass of substances (drug plus drug carrier) dissolved in coating solutions. Components were prepared by weighing, using the precision balance Atilon ATL-224 (Aculab Inc., Massachusetts, USA).

**Preparation of anti-microbial sutures**

Sutures were cut into 40 cm pieces followed, by coating them in a dip process in flasks under aseptic conditions. The closed flasks were placed on a thermo-shaker (Heidolph Instruments GmbH, Germany) for 2 minutes at 35°C and 150 rpm, in order to achieve reproducible coating weights. After drying for at least 2 hours the coating weight was determined by using the precision balance related to the weight of uncoated sutures. The amount of drug normalized per length of suture (µg/cm) was calculated for each concentration (Table 1).

**Tensile strength test**

For tensile strength testing the uncoated plain PGA sutures (Gunze), PGA Resorba, Vicryl, Vicryl Plus, and exemplarily novel coated sutures CL22, CP22 were measured. The mechanical strength of individual surgical sutures (n = 5) was determined according to the European Pharmacopoeia (Ph. Eur. 7.0/0667: required minimum for USP 1 sutures is 50.8 N) using the tensile testing instrument Zwick 8253 (Zwick GmbH, Germany).

**Drug release from fatty acid drug delivery coatings**

Drug release kinetics of coated sutures were measured over a time period of 96 hours in phosphate-buffered saline (PBS). For this purpose sutures of 2 cm length (n = 3) were eluted in 1 ml PBS inside a thermostorer MHR 23 (HLC-Biotech, Germany) at 37°C and 200 rpm. After 1 h, 3 h, 5 h, 7 h, 24 h, 48 h, 72 h and 96 h, elution media was taken out and replaced by fresh PBS. Amount of released chlorhexidine was measured by absorption at 280 nm in a microplate spectrophotometer Multiskan Go (Thermo Fisher Scientific GmbH, Germany). Measured drug concentrations were normalized to length of suture samples and drug elution profiles were recorded by cumulating the released drug amounts over time. The percentage of released chlorhexidine was calculated referring to loaded drug per cm length.
Anti-bacterial efficacy of coated sutures via zones of inhibition

Anti-microbial efficacy was determined in Agar plate diffusion tests by using the strain *Staphylococcus aureus* (ATCC 49230), the main pathogen of implant-associated infections [32,33]. According to CLSI criteria, bacterial suspensions were prepared to 0.5 McFarland standard [34]. On each Agar plate 1 ml of this suspension was uniformly distributed. Coated sutures with 3 cm length (n = 3) were placed onto these inoculated Agar plates and incubated at 37°C for 24 hours. Inhibition zones were measured (in mm), with a calliper perpendicular to the middle of the threads. Novel coated sutures and Vicryl Plus were put on Agar plates every 24 hours with fresh bacterial lawns and incubated overnight. Over the following days we measured the inhibition zones. Analogous to Ming et al. [12] this procedure was repeated by using the same samples for several days to recognize the remaining anti-bacterial activity until no detectable inhibition zone was left.

Cytotoxicity study

According to ISO 10993-5:2009, mouse fibroblasts L-929 (DSMZ, Germany) were used for in vitro cytotoxicity testing of coated sutures. The evaluation was performed by measuring the metabolic activity of cells in the presence of eluates from coated sutures via a WST-1 cell proliferation assay (Roche Diagnostics GmbH, Germany). Cells were cultivated in the corresponding media (D-MEM 4.5 g/l D-glucose, Biochrom AG, Germany) containing 10% fetal bovine serum at 37°C and 5.0% CO2 in a humidified atmosphere. Pre-cultures started at 10,000 cells/well inside 96 well microtiter plates, incubated for 24 hours in 200 μl D-MEM. Simultaneously, eluates were generated by eluting coated sutures of 1 cm length (n = 7) in 1.5 ml D-MEM for 24 hours on a thermomixer at 37°C and 300 rpm. After 24 hours cell media was swapped with eluates. Finally, after 48 hours referred to the WST-1 protocol the metabolic activity was measured by quantitative detection of formazan at 405 nm in a spectral photometer. Metabolic activities obtained were referred to measured by quantitative detection of formazan at 405 nm in a cell media was swapped with eluates. Finally, after 48 hours

| Tensile strength           | Gunze | PGA Resorba | CL22 | CP22 | Vicryl | Vicryl Plus |
|---------------------------|-------|-------------|------|------|--------|------------|
| mean Fmax (N)             | 73.7  | 81.6        | 80.3 | 75.9 | 78.3   | 72.2       |
| ± standard deviation (N)  | 3.0   | 1.6         | 1.5  | 2.2  | 2.2    | 2.2        |

Mean values of the maximum force Fmax (n = 5) for uncoated, commercial and novel coated sutures CL22 and CP22 in example are given above. The required minimum for USP 1 surgical sutures at 50.8 N according to European Pharmacopoeia, was reached for all tested sutures.

doi:10.1371/journal.pone.0101426.t002

Drug release from fatty acid drug delivery coatings

Released drug concentrations in PBS eluates normalized by length were compared to each other for chlorhexidine laurate coatings (Figure 2A) and chlorhexidine palmitate coatings (Figure 2B).

Anti-bacterial efficacy of coated sutures via zones of inhibition

Anti-microbial efficacy of coated sutures was daily assessed by using an Agar diffusion assay over several days (Figure 3A). Sutures coated with chlorhexidine in lauric acid (Figure 3B, a) revealed large *S. aureus* inhibition zones after 24 hours of 7.1 mm (CL11), 8.2 mm (CL22) and 8.7 mm (CL33). Inhibition zones during the first three to four days of experiments averaged up to 1.7 mm for CL11, 3.4 mm for CL22 and 2.5 mm for CL33. After the fifth day no inhibition zones were detectable. Chlorhexidine in palmitic acid coatings showed similar results (Figure 3B, b). Inhibition zones after 24 hours were assessed at 4.9 mm (CP11), 7.1 mm (CP22) and 8.9 mm (CP33). The dimensions and durations of the zones of inhibition were dependent on drug concentrations. CP11 ended up after fourth day of experiment, whereas CP22 and CP33 ended up after the fifth day of experiment. The triclosan containing Vicryl Plus showed large inhibition zones after 24 hours on Agar plates with 19.8 mm (Figure 3B, c) lasting for at least nine days and ending up with 1.7 mm zones. The bioavailability of the antiseptics from the fatty
Acid delivery systems was corroborated by the microbial experiments.

Cytotoxicity study

Cytotoxicity tests were performed via eluates from individual coated sutures and references. All metabolic activities were referred to L-929 cell samples used as growth reference without sutures. Coatings with chlorhexidine in lauric acid ended with metabolic cell activities at 69.1±7.0% (CL11), 0.9±0.5% (CL22) and 0.3±0.3% (CL33). Chlorhexidine in palmitic acid coatings showed activities at 74.5±29.3% (CP11), 1.1±1.9% (CP22) and no more cell activity for CP33 sutures. The fatty acid coated references identified metabolic activities at 87.8±13.2% and 80.4±13.4% (lauric acid, palmitic acid). Eluates from uncoated sutures reached a metabolic activity at 100.8±9.7% (Gunze). Vicryl Plus eluates demonstrated activities at 98.7±7.1% (Figure 4).

Discussion

Surgical site infection still poses a major complication in surgery. Sutures can cause so called suture-associated infections, induced by proliferation of adhering pathogens. Adhering bacteria enter wounds by capillary action and form infamous biofilms, leading to chronic infections [8]. Anti-microbial coatings for surgical sutures can solve that problem via protecting sutures by inhibiting bacterial growth.

In the present study we developed new anti-microbial suture coatings based on fatty acid carriers using chlorhexidine and adjusting their drug concentrations. The aim was to identify anti-microbial sutures posing effective protection against microbes while being biocompatible in regard to eukaryotic cells. Fatty acids constitute a lubricating film and are state of the art in order to reduce the unwanted sewing effect of sutures. This kind of drug-release system still allows slow-release properties, because of low solubility of fatty acid carriers in aqueous environments [37,38].
In a reproducible dip coating process we developed several coating types at various concentrations based on chlorhexidine with lauric or palmitic acid (CL, CP). Coated sutures obtained were tested systematically regarding their tensile strength, drug release, anti-microbial efficacy against \textit{S. aureus}, and cytotoxicity using a WST-1 assay.

Tensile strength of coated PGA sutures was just negligibly influenced by the dip coating process using ethanol. All coated sutures undergoing this process showed much higher maximum strength values than required by the Ph. Eur. standards for USP1 resorbable sutures. The mean strength values of novel coated sutures were comparable to commercially available PGA sutures (PGA Resorba, Vicryl, Vicryl Plus). Therefore, no negative influence of coatings on in vivo degradation time for anti-microbial coated PGA sutures is to be expected. Flexibility of coated sutures remained steady, no delamination was observed after mechanical stress tests. Consequently, no delamination is to be expected while pulling them through the tissue.

Released drug concentration in PBS for chlorhexidine coated sutures showed a continuous drug release for 96 hours with initial rapid release slowing down significantly after 7 hours. In general, drug release should be as slow as possible, however, anti-microbially effective to inhibit pathogens as long as possible, to achieve long-term protection of the coated biomaterial. Drug release is strongly dependent on drug concentration inside coatings. Referring to drug carriers, palmitic acid coatings showed slower drug release values over time than lauric acid coatings with similar anti-microbial efficacies. Moreover, lesser amounts of chlorhexidine were released from palmic acid coatings. Therefore, anti-microbial effects of coated sutures using palmic acid carrier should have a higher potency for long-term protection in vivo than coatings using lauric acid carriers.

Novel coated sutures showed high anti-microbial efficacy in agar diffusion tests against \textit{S. aureus}. Anti-bacterial tests on agar plates mimic the tissue contact transferring substances by diffusion. All coated sutures generated inhibition zones for more than 24 hours and documented efficacies over several days, similar to Vicryl Plus. Inhibition zones of CP11, on the second day, showed a little increase, presumably a consequence of non-uniform contact of suture samples on Agar surfaces and therefore diffusion problems. The release of chlorhexidine indicated by the inhibition zones is faster during the first days compared to triclosan, because of its much higher solubility in aqueous environments like PBS or Agar. This faster consumption of substances on sutures leads to earlier leaching of inhibition zones. On the one hand, this could be a benefit, because a sufficient release of antiseptics in the wound area in the first days might be an important factor to prevent a potential early wound infection. The long-term efficacy of chlorhexidine coated sutures against \textit{S. aureus} lasted up to 5 days at high levels. Regarding drug concentrations, the dimension of inhibition zones over time did not differ greatly. Thus, even the low drug content of 11 µg/cm can almost be as effective as 22 or

![Figure 3. Measuring anti-bacterial efficacy of coated sutures via zones of inhibition. A) Principle of measuring inhibition zones in a longitudinal analysis on the example of a Vicryl Plus suture, in order to achieve anti-microbial effectiveness over several days. B) Anti-microbial efficacies on Agar plates with \textit{S. aureus} lawns (2×10⁶ cfu/ml) for a) chlorhexidine lauric acid and b) chlorhexidine palmitic acid coated sutures. Coated suture samples with three different chlorhexidine concentrations 11, 22 and 33 µg/cm. c) Vicryl Plus as reference for commercial anti-microbial sutures. doi:10.1371/journal.pone.0101426.g003](image-url)
rather 33 μg/cm in protecting surgical sutures, without depletion of the anti-microbial drug on sutures.

Biocompatibility studies on coated sutures demonstrated acceptable cytotoxicities only for the lowest drug concentrations at 11 μg/cm independent from the fatty acid used. Such sutures fulfilled the at least required 70% remaining metabolic activity of L-929 cells to claim non-cytotoxicity according to ISO 10993-5:2009. Nevertheless, those sutures still have a high anti-microbial efficacy. Therefore, 11 μg/cm chlorhexidine coated sutures are potential candidates for further pre-clinical and human in vivo studies. In general, a strong dose-dependent effect for anti-microbial coated sutures was recognized regarding cytotoxicity. To improve biocompatibility a fine tuning with reduction of drug concentration, i.e., from 11 to 9 μg/cm without sacrificing the high anti-microbial efficacies seems promising.

There are limitations of our study, at first, the use of only one bacterial strain, *S. aureus*, for testing efficacy of coated anti-microbial sutures. In vitro tests should be performed to further prove efficacy against other relevant types of pathogens. Second, no effects on biofilms by anti-microbial coated sutures were investigated but bacterial cultures on agar and in suspensions are most common for first evaluation. For that purpose in vitro experiments with microbiological biofilm models are necessary. Third, other antiseptic substances should be identified and investigated regarding biocompatibility and anti-microbial efficacy.

To sum up, we demonstrated a prototypical coating process to provide anti-microbial sutures at high reproducible quality. Mechanical strength tests indicated negligible influences of the coating process comparable to commercial sutures and beyond the Ph. Eur. required strength values for resorbable sutures. Drug release from the novel coated sutures in aqueous media revealed to be dependent on dose, and the entity of the fatty acid carrier. We identified that all used novel chlorhexidine coated sutures proved high anti-bacterial efficacy. Duration of inhibition zones on Agar plates was dependent on the chlorhexidine dose, however there seemed to be no influence from fatty acid carriers. Biocompatibility testing of coated sutures also indicated strong dose dependency.

**Conclusions**

In this study we developed novel chlorhexidine coatings for anti-microbial surgical sutures with three different antiseptic concentrations based on palmitic and lauric acid carriers. We demonstrated their high anti-microbial efficacy against *S. aureus* in vitro. In particular, chlorhexidine coated sutures with 11 μg/cm concentration proved acceptable cytotoxicity according to ISO 10993-5 and simultaneously high anti-microbial protection over several days. Such coated sutures represent an alternative in the case of triclosan-resistance for prophylactic sutures. The aim is to support surgeons with an effective weapon to reduce suture-associated surgical site infections. However, further pre-clinical and clinical trials are necessary to confirm safety and efficacy in vivo.

**Acknowledgments**

We would like to express our great appreciation to Dr. K.-D. Kühn (Heraeus Medical GmbH) and Dr. K.-H. Sorg (Resorba GmbH) for their kind supply of materials. Also, many thanks to J. Hintermair (Zentralin-
stit für Medizintechnik IMETUM, TU München) for supplying the mouse fibroblastic cell line L-929. Many thanks to J. Tübel (cell culture laboratory, Klinikum rechts der Isar, Klinik für Orthopädie, TU München) for her great assistance in cell biological experiments. Also, many thanks to P. Föhr (biomechanics laboratory, Klinikum rechts der Isar, Klinik für Orthopädie, TU München) for his great guidance in biomechanical testing.

References

1. Young B, Ng TM, Teng C, Ang B, Tai HY, et al. (2011) Nonconcordance with surgical site infection prevention guidelines and rates of surgical site infections for general surgical, neurological, and orthopedic procedures. Antimicrobial Agents and Chemotherapy 55: 4659–4663.

2. Hranjec T, Swenson BR, Sawyer RG (2010) Surgical site infection prevention: who do we do it. Surgical Infections 11: 289–294.

3. Leaper DJ (2010) Surgical-site infection. The British journal of surgery 97: 1601–1602.

4. Barac J, Huazar O, Sajjadi SG, Hovarth OP (2011) Surgical site infections after abdominal closure in colorectal surgery using triclosan-coated absorbable suture (PDS Plus) vs. uncoated sutures (PDS II): a randomized multicenter study. Surgical Infections 12: 483–489.

5. Barnett TE (2007) The Not-So-Hidden Costs of Surgical Site Infections. AORN journal 86: 243–258.

6. Eiff C, Jansen B, Kohnen W, Becker K (2005) Infections Associated with Medical Devices. Drugs 65: 179–214.

7. Geiger D, Debus ES, Ziegler UE, Larena-Avellaneda A, Frosch M, et al. (2005) Capillary activity of surgical sutures and suture-dependent bacterial transport: a qualitative study. Surg Infect (Larchmt) 6: 377–383.

8. Kathju S, Nutico L, Hall-Stoodley L, Post JC, Ehrlich GD, et al. (2009) Chronic surgical site infection due to suture-associated polymicrobial biofilm. Surg Infect (Larchmt) 10: 457–461.

9. Katz S, Ehrar M, Mirelman D (1981) Bacterial adherence to surgical sutures. A possible factor in suture induced infection. Ann Surg 194: 35–41.

10. Ming X, Rothenburger S, Nicholls MM (2008) In vivo and in vitro antibacterial efficacy of PDS (polydioxanone with triclosan) suture. Surgical Infections 9: 451–457.

11. Justinger C, Schmid J, Sperling J, Kollmar O, Richter S, et al. (2011) Triclosan-coated sutures reduce wound infections after hepatoportal surgery—a prospective non-randomized clinical pathway driven study. Langenbeck’s Archives of Surgery: 1–6.

12. Justinger C, Schmid J, Sperling J, Kollmar O, Richter S, et al. (2011) Triclosan-coated sutures reduce wound infections after hepatoportal surgery—a prospective non-randomized clinical pathway driven study. Langenbeck’s Archives of Surgery: 1–6.

13. Justinger C, Schmid J, Sperling J, Kollmar O, Richter S, et al. (2011) Triclosan-coated sutures reduce wound infections after hepatoportal surgery—a prospective non-randomized clinical pathway driven study. Langenbeck’s Archives of Surgery: 1–6.

14. Justinger C, Schmid J, Sperling J, Kollmar O, Richter S, et al. (2011) Triclosan-coated sutures reduce wound infections after hepatoportal surgery—a prospective non-randomized clinical pathway driven study. Langenbeck’s Archives of Surgery: 1–6.

15. Stone J, Gruber TJ, Rozzelle CJ (2010) Healthcare savings associated with triclosan-inhibiting polymer-suture use. JAMA 304: 1157–1157.

16. Wang ZX, Jiang CP, Cao Y, Ding YT (2013) Systematic review and meta-analysis of triclosan-coated sutures for the prevention of surgical-site infection. International Wound Journal 8: 556–566.

17. Fujita T (2010) Antibiotic-coated surgical sutures against surgical site infection. Surgery 147: 464–465; author reply 463–466.

18. Chang WK, Sinivasa S, Morton R, Hill AG (2012) Triclosan-incorporated sutures to decrease surgical site infections: systematic review and meta-analysis of randomized trials. Ann Surg 253: 834–839.

19. Williams N, Snellstrand H, Goyal S, Ivens N, Leaper DJ (2011) Randomized trial of antimicrobial-coated sutures to prevent surgical site infection after breast cancer surgery. Surgical Infections 12: 469–474.

20. Mingmalairak C, Unghakorn P, Paochareon V (2009) Efficacy of antimicrobial coating suture coated polybutyric 910 with tricosa (Vicryl plus) compared with polybutylic 910 (Vicryl) in reduced surgical site infection of appendectomy, double blind randomized control trial, preliminary safety report. J Med Assoc Thai 92: 770–775.

21. Cooney CM (2010) Triclosan comes under scrutiny. Environ Health Perspect 118: A242.

22. Yazdankhah SP, Scheie AA, Hoby EA, Lunested BT, Her E, et al. (2006) Triclosan and antimicrobial resistance in bacteria: an overview. Microbial drug resistance 12: 83–90.

23. Acelo AE, Larson EL, Levy SB (2007) Consumer antibacterial soaps: effective or just risky? Clin Infect Dis 45 Suppl 2: S137–147.

24. Segers P, Speekenbrink RG, Ubink BT, van Ogtrop MI, de Mol BA (2006) Prevention of nosocomial infection in cardiac surgery by decontamination of the nasopharynx and oropharynx with chlorhexidine gluconate: a randomized controlled trial. JAMA 296: 2460–2466.

25. Rupp ME, Lisco SJ, Lippet PA, Perl TM, Keating K, et al. (2005) Effect of a second-generation venous catheter impregnated with chlorhexidine and silver sulfadiazine on central catheter-related infections: a randomized, controlled trial. Ann Intern Med 143: 570–570.

26. Sanders D, Lambie J, Bond P, Mooste R, Steer JA (2013) An in vitro study assessing the effect of mesh morphology and suture fixation on bacterial adherence. Hernia 17: 779–789.

27. Timsit JF, Minoz O, Mourviller B, Sounuane B, Garrouste-Orgeas M, et al. (2012) Randomized controlled trial of chlorhexidine dressing and highly adhesive dressing for preventing catheter-related infections in critically ill adults. Am J Respir Crit Care Med 186: 1272–1276.

28. Menders G, Athar Ali N, Aagaard K, Sangi-Haghpeykar H (2012) Chlorhexidine-alcohol compared with povidone-iodine for surgical-site antisepsis in cesarean deliveries. Obstet Gynecol 120: 1037–1037.

29. Suwanpimolkul G, Pongkumpai M, Suankratay C (2008) A randomized trial of 2% chlorhexidine tincture compared with 10% aqueous povidone-iodine for venipuncture site disinfection: Effects on blood culture contamination rates. J Infect 56: 354–359.

30. Hulner NO, Mathers R, Koban I, Randell C, Muller G, et al. (2010) Efficacy of chlorhexidine, povidexan and tissue-tolerable plasma against Pseudomonas aeruginosa biofilms grown on polyesterene and silicone materials. Skin Pharmacology and Physiology 23 Suppl: 28–34.

31. Mail FD, Zlotyck J, Obermeier A, Fries S, Vogt S, et al. (2009) New Anti-infective Coatings of Surgical Sutures Based on a Combination of Antisepsis and Fatty Acids. Journal of Biomaterials Science, Polymer Edition 20: 1439–1449.

32. Schierholz JM, Beuth J (2001) Implant infections: a haven for opportunistic bacteria. Journal of Hospital Infection 49: 87–93.

33. Steinwein RA, D’Arrozic RO (2001) Device-Associated Infections: A Macro-problem that Starts with Microadherence. Clinical Infection Diseases 33: 1567–1572.

34. CLSI (2012) Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically. Approved Standard—Ninth Edition. CLSI document M07-A9 Clinical and Laboratory Standards Institute.

35. Ethicon (2010) Ihr zusätzlicher Schutz vor postoperativen Wundinfektionen, PLUS Nahtmaterial – ein neues Maß an Sicherheit Brochures Plus sutures (B-nr 1957–1963.

36. Timsit JF, Minoz O, Mourviller B, Sounuane B, Garrouste-Orgeas M, et al. (2012) Randomized controlled trial of chlorhexidine dressing and highly adhesive dressing for preventing catheter-related infections in critically ill adults. Am J Respir Crit Care Med 186: 1272–1276.

37. Mail FD, Zlotyck J, Obermeier A, Fries S, Vogt S, et al. (2009) New Anti-infective Coatings of Surgical Sutures Based on a Combination of Antisepsis and Fatty Acids. Journal of Biomaterials Science, Polymer Edition 20: 1439–1449.

38. Obermeier A, Meier FD, Schwabe J, Zimmermann A, Kuhn KD, et al. (2012) Novel fatty acid gentamicin salts as slow-release drug carrier systems for anti-infective protection of vascular biomaterials. J Mater Sci Mater Med 23: 1675–1683.

Author Contributions

Conceived and designed the experiments: AO JS SW FDM MS RvER AS. Performed the experiments: AO JS SW FDM. Analyzed the data: MS RvER AS. Contributed reagents/materials/analysis tools: MS RvER AS. Wrote the paper: AO JS SW FDM MS RvER AS.